NBY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NBY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
NovaBay Pharmaceuticals's change in working capital for the quarter that ended in Dec. 2023 was $0.54 Mil.
NovaBay Pharmaceuticals's change in working capital for the fiscal year that ended in Dec. 2023 was $0.75 Mil.
It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).
The historical data trend for NovaBay Pharmaceuticals's Change In Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.75 Mil.
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.
Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.
Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC
Consolidated Statements of Cash Flows | Fiscal Years Ended | January 31, | (Amounts in millions) |
Cash flows from operating activities: | 2014 | 2013 | 2012 |
Changes in certain assets and liabilities, net of effects of acquisitions: | |||
Receivables, net | (566) | (614) | (796) |
Inventories | (1,667) | (2,759) | (3,727) |
Accounts payable | 531 | 1,061 | 2,687 |
Accrued liabilities | 103 | 271 | (935) |
Accrued income taxes | (1,224) | 981 | 994 |
For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.
Tommy Law | officer: Interim CFO | 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608 |
Jeffrey Kunin | officer: President, DERMAdoctor, LLC | 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150 |
Audrey Kunin | officer: Chief Product Officer | 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150 |
Justin Hall | officer: General Counsel | 5980 HORTON STREET, SUITE 550, EMERYVILLE CA 94608 |
Yongxiang Zheng | director | NO.10, UNIT 1, LIJING VILLA, TIANZHU, SHUNYI DISTRICT, BEIJING F4 101316 |
Julie Garlikov | director | 2420 17TH STREET, SUITE 220, DENVER CO 80202 |
Andrew D. Jones | officer: CFO and Treasurer | 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608 |
Mijia Wu | director | SUITE 6C, BLDG 3, YOU YOU CENTURY PLAZA, NO 428 YANG GAO SOUTH ROAD, SHANGHAI F4 CHINA |
Jian Ping Fu | 10 percent owner | LEVEL 1, BLDG 1, GREENWOOD BUSINESS PARK, 301 BURWOOD HWY, BURWOOD C3 3125 |
Wang Xu | officer: NEO - Sr Mgr and Controller | 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608 |
Swan Sit | director | 95 JACKSON STREET, NEWTON MA 02459 |
Yenyou Zheng | director | 1055 WEST HASTINGS STREET, SUITE 1980, VANCOUVER A1 V6E 2E9 |
Xiaopei Wang | director | 2/44 FRANKLIN ROAD, DONCASTER EAST C3 3109 |
Jason Philip Raleigh | officer: Interim CFO and Treasurer | 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608 |
Pioneer Pharma (hong Kong) Co Ltd | 10 percent owner | FLAT 2605, 26/F TRENDY CENTRE, 682 CASTLE PEAK ROAD, KOWLOON K3 000000 |
From GuruFocus
By PRNewswire PRNewswire • 10-02-2020
By PRNewswire PRNewswire • 05-15-2019
By PRNewswire PRNewswire • 04-20-2020
By PRNewswire PRNewswire • 07-13-2020
By gurufocus • 08-28-2009
By Marketwired Marketwired • 08-09-2019
By Marketwired Marketwired • 08-09-2019
By PRNewswire PRNewswire • 05-14-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.